McKesson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade McKesson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MCK

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. 

CEO
Brian Scott Tyler
CEOBrian Scott Tyler
Employees
45,000
Employees45,000
Headquarters
Irving, Texas
HeadquartersIrving, Texas
Founded
1833
Founded1833
Employees
45,000
Employees45,000

MCK Key Statistics

Market cap
103.18B
Market cap103.18B
Price-Earnings ratio
25.70
Price-Earnings ratio25.70
Dividend yield
0.37%
Dividend yield0.37%
Average volume
533.55K
Average volume533.55K
High today
$838.46
High today$838.46
Low today
$820.13
Low today$820.13
Open price
$824.24
Open price$824.24
Volume
147.37K
Volume147.37K
52 Week high
$895.58
52 Week high$895.58
52 Week low
$570.51
52 Week low$570.51

Stock Snapshot

The current McKesson(MCK) stock price is $836.00, with a market capitalization of 103.18B. The stock trades at a price-to-earnings (P/E) ratio of 25.70 and offers a dividend yield of 37.1%.

As of 2026-01-14, McKesson(MCK) stock has fluctuated between $820.13 and $838.46. The current price stands at $836.00, placing the stock +1.9% above today's low and -0.3% off the high.

The McKesson(MCK)'s current trading volume is 147.37K, compared to an average daily volume of 533.55K.

In the last year, McKesson(MCK) shares hit a 52-week high of $895.58 and a 52-week low of $570.51.

In the last year, McKesson(MCK) shares hit a 52-week high of $895.58 and a 52-week low of $570.51.

MCK News

TipRanks 4h
McKesson price target raised to $968 from $928 at Baird

Baird analyst Eric Coldwell raised the firm’s price target on McKesson (MCK) to $968 from $928 and keeps an Outperform rating on the shares. The firm updated it...

Simply Wall St 20h
Is Wider Rapiblyk Access Deepening McKesson’s Specialty Edge Or Just Incremental Volume For MCK?

AOP Health US, LLC recently announced that its critical care beta-blocker Rapiblyk (landiolol) is now broadly available across the United States through major d...

Is Wider Rapiblyk Access Deepening McKesson’s Specialty Edge Or Just Incremental Volume For MCK?

Analyst ratings

80%

of 20 ratings
Buy
80%
Hold
15%
Sell
5%

People also own

Based on the portfolios of people who own MCK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .